Dexilant and Dexilant Solutab are prescription drugs in a class of drugs known as proton pump inhibitors (PPIs). According to the Jere Beasley Report, there were 5,635 reports of side effects linked to the drugs’ use between 2009, when the Food and Drug Administration (FDA) approved it, and 2016.
Nearly six percent of those reporting side effects reported suffering from vertigo. Some consumers who reported experiencing vertigo used Dexilant for less than a month while others used it for as long as six months.
Dexilant and Dexilant Solutab are manufactured by Takeda Pharmaceutical Company Ltd. Dexilant was initially approved for adult patients to treat all grades of erosive esophagitis (EE); maintenance of healed EE and relief of heartburn; and treatment of symptomatic non-erosive gastroesophageal reflux disease (GERD). Dexilant Solutab was approved for adult patients for the maintenance of healed EE and relief of heartburn and treatment of symptomatic non-erosive GERD. In 2016, the FDA expanded approval for use of Dexilant and Dexilant Solutab by patients 12 to 17 years of age in the approved indications.
Prescribing information identifies dizziness as one of the “less common adverse reactions.” The less common adverse reactions occur in less than 2 percent of the reported side effects. However, it fails to warn patients that serious or repeated vertigo is a potential adverse side effect. Additional adverse side effects include hypertension (high blood pressure) and an increased risk of stroke for patients taking 60 mg of Dexilant two times daily.
Beasley Allen has previously described additional adverse effects linked to the use of PPIs including Acute Interstitial Nephritis, an increased risk of Acute Kidney Injury (or Acute Renal Failure) and Chronic Kidney Disease.
* * *
Beasley Allen attorney James Lampkin works in the firm’s Mass Torts section handling claims on behalf of patients negatively affected by medical devices and medications. He is currently investigating cases involving serious or repeated vertigo and Dexilant use. For more information about these types of claims, contact him by email at James.Lampkin@BeasleyAllen.com.
Jere Beasley Report (April 2017)